Optimising conditions for radiolabelling of DOTA-peptides with 90Y, 111In and 177Lu at high specific activities

被引:179
作者
Breeman, WAP
de Jong, M
Visser, TJ
Erion, JL
Krenning, EP
机构
[1] Erasmus MC Rotterdam, Dept Nucl Med, NL-3015 GD Rotterdam, Netherlands
[2] Erasmus MC Rotterdam, Dept Internal Med, NL-3015 GD Rotterdam, Netherlands
[3] BioSynthema, St Louis, MO USA
关键词
DOTA; radiolabelling; specific activity;
D O I
10.1007/s00259-003-1142-0
中图分类号
R8 [特种医学]; R445 [影像诊断学];
学科分类号
1002 ; 100207 ; 1009 ;
摘要
DOTA-conjugated peptides, such as [DOTA(0), Tyr(3)]octreotide (DOTATOC) and [DOTA(0),Tyr(3)]octreolate (DOTA-tate), can be labelled with radionuclides such as Y-90, In-111 and Lu-177. These radiolabelled somatostatin analogues are used for peptide receptor radionuclide therapy (PRRT). Radioligands for PRRT require high specific activities. However, although these radionuclides are produced without addition of carrier, contaminants are introduced during production and as decay products. In this study, parameters influencing the kinetics of labelling of DOTA-peptides were investigated and conditions were optimised to obtain the highest achievable specific activity. The effects of contaminants were systematically investigated, concentration dependently, in a test model mimicking conditions for labelling with minimal molar excess of DOTA-peptides over radionuclide. Kinetics of labelling of DOTA-peptides were optimal at pH 4-4.5; pH <4 strongly slowed down the kinetics. Above pH 5, reaction kinetics varied owing to the formation of radionuclide hydroxides. Labelling with Y-90 and Lu-177 was completed after 20 min at 80degreesC, while labelling with In-111 was completed after 30 min at 100degreesC. The effects of contaminants were systematically categorised, e.g. Cd2+ is the target and decay product of In-111, and it was found to be a strong competitor with In-111 for incorporation in DOTA. In contrast, Zr4+ and Hf4+, decay products of Y-90 and Lu-177, respectively, did not interfere with the incorporation of these radionuclides. The following conclusions are drawn: (a) DOTA-peptides can be radiolabelled at high specific activity; (b) reaction kinetics differ for each radionuclide; and (c) reactions can be hampered by contaminants, such as target material and decay products.
引用
收藏
页码:917 / +
页数:5
相关论文
共 17 条
[1]  
BAKKER WH, 1991, J NUCL MED, V32, P1184
[2]  
BAKKER WH, 1991, J NUCL MED, V32, P1999
[3]  
BREEMAN W, 2002, EUR J NUCL MED, V29, pP690
[4]   Somatostatin receptor-mediated imaging and therapy: basic science, current knowledge, limitations and future perspectives [J].
Breeman, WAP ;
de Jong, M ;
Kwekkeboom, DJ ;
Valkema, R ;
Bakker, WH ;
Kooij, PPM ;
Visser, TJ ;
Krenning, EP .
EUROPEAN JOURNAL OF NUCLEAR MEDICINE, 2001, 28 (09) :1421-1429
[5]   G-protein coupled receptor kinases as modulators of G-protein signalling [J].
Bünemann, M ;
Hosey, MM .
JOURNAL OF PHYSIOLOGY-LONDON, 1999, 517 (01) :5-23
[6]  
ERION JL, 1999, J NUCL MED, V40
[7]   EFFECT OF LOXIGLUMIDE (CR-1505) ON BOMBESIN-STIMULATED AND MEAL-STIMULATED PLASMA CHOLECYSTOKININ IN MAN [J].
JANSEN, JBMJ ;
JEBBINK, MCW ;
DOUGLAS, BR ;
LAMERS, CBHW .
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 1990, 38 (04) :367-370
[8]  
Krenning EP, 2000, RECENT RES CANCER, V153, P1
[9]  
Kukis DL, 1998, J NUCL MED, V39, P2105
[10]  
Kwekkeboom D, 2000, J NUCL MED, V41, P1704